Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TIMOTHY G MORIARTY

Allopathic & Osteopathic Physicians General Practice

NPI
1578539805
CMS profile
116420
Location
PANAMA CITY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,569.25

39 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,111.60 37
Travel and Lodging $457.65 2

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TIMOTHY G MORIARTY

NPI 1578539805 · CMS profile ID 116420

Allopathic & Osteopathic Physicians / General Practice

PANAMA CITY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578539805?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TIMOTHY G MORIARTY, NPI 1578539805, CMS profile ID 116420. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578539805?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). TIMOTHY G MORIARTY, NPI 1578539805, CMS profile ID 116420. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578539805?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
TIMOTHY G MORIARTY, NPI 1578539805, CMS profile ID 116420, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1578539805?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

39 matching records · $1,569.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 39 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–39 of 39.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Mylan Specialty L.P. $23.1411/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694814679 CMS
GlaxoSmithKline, LLC. $22.4911/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670687595 CMS
GlaxoSmithKline, LLC. $10.9811/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671252555 CMS
AstraZeneca Pharmaceuticals LP $14.9611/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685792493 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $69.6111/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700105793 CMS
GlaxoSmithKline, LLC. $17.9410/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670793433 CMS
AstraZeneca Pharmaceuticals LP $324.0510/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685022815 CMS
AstraZeneca Pharmaceuticals LP $344.0010/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685110877 CMS
AstraZeneca Pharmaceuticals LP $133.6010/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685184429 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.8610/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700041695 CMS
GlaxoSmithKline, LLC. $20.6410/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670911849 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $29.9109/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700105795 CMS
GlaxoSmithKline, LLC. $24.5809/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670832888 CMS
AstraZeneca Pharmaceuticals LP $14.9009/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685361437 CMS
GlaxoSmithKline, LLC. $23.4309/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671451035 CMS
GlaxoSmithKline, LLC. $20.4208/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671420215 CMS
AstraZeneca Pharmaceuticals LP $18.3008/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685338879 CMS
AstraZeneca Pharmaceuticals LP $85.5507/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685304715 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.5407/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700105797 CMS
AstraZeneca Pharmaceuticals LP $14.4307/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685767121 CMS
GlaxoSmithKline, LLC. $22.1306/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671470145 CMS
GlaxoSmithKline, LLC. $19.7606/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670720969 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $3.6006/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700105799 CMS
Regeneron Healthcare Solutions, Inc. $14.0906/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673443001 CMS
GENZYME CORPORATION $18.9105/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694028203 CMS
GlaxoSmithKline, LLC. $18.7304/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671245935 CMS
GlaxoSmithKline, LLC. $20.4504/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670364527 CMS
AstraZeneca Pharmaceuticals LP $17.6404/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685120697 CMS
Mylan Specialty L.P. $18.1404/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694781967 CMS
GlaxoSmithKline, LLC. $16.4903/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671418865 CMS
AstraZeneca Pharmaceuticals LP $20.0103/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685928039 CMS
GlaxoSmithKline, LLC. $16.9903/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670370133 CMS
GlaxoSmithKline, LLC. $15.6302/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671471369 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.2402/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700105791 CMS
GlaxoSmithKline, LLC. $16.9902/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670763681 CMS
GlaxoSmithKline, LLC. $9.5402/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671330853 CMS
GlaxoSmithKline, LLC. $20.8901/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671454273 CMS
GlaxoSmithKline, LLC. $16.0201/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671440063 CMS
AstraZeneca Pharmaceuticals LP $11.6701/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685976027 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,569.25 39

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019
Generated from
OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2021 Principal investigator $81,304.10 30
PY2020 Principal investigator $303,748.50 51
PY2019 Recipient $1,188.88 12
PY2019 Principal investigator $261,356.49 38

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,720.10 12/31/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma No dispute reported 06/30/2026 736737023
Principal investigator 1 SANOFI US SERVICES INC. $7,363.58 12/21/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744024893
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $31.00 12/18/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma No dispute reported 06/30/2026 740105991
Principal investigator 1 GlaxoSmithKline, LLC. $3,200.00 12/12/2020 Non-covered Recipient Entity
EMERALD COAST RESEARCH ASSOCIATES
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 734916533
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $735.68 11/05/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma No dispute reported 06/30/2026 740105993
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $389.46 11/05/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma No dispute reported 06/30/2026 740105995
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $782.07 11/05/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma No dispute reported 06/30/2026 740105997
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,570.18 11/05/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma No dispute reported 06/30/2026 740105999
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,325.92 11/05/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma No dispute reported 06/30/2026 740106001
Principal investigator 1 SANOFI US SERVICES INC. $7.16 11/03/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 753386313
Principal investigator 1 SANOFI US SERVICES INC. $2,835.00 11/03/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 753386315
Principal investigator 1 SANOFI US SERVICES INC. $1,960.00 11/03/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 753386317
Principal investigator 1 SANOFI US SERVICES INC. $472.50 11/03/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 753386319
Principal investigator 1 SANOFI US SERVICES INC. $19.62 11/03/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 753386321
Principal investigator 1 SANOFI US SERVICES INC. $350.00 11/03/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 753386323
Principal investigator 1 SANOFI US SERVICES INC. $269.36 11/03/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 753386325
Principal investigator 1 SANOFI US SERVICES INC. $268.21 11/03/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 753386327
Principal investigator 1 SANOFI US SERVICES INC. $18,015.09 11/03/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 753386331
Principal investigator 1 SANOFI US SERVICES INC. $645.21 10/05/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744026313
Principal investigator 1 SANOFI US SERVICES INC. $1,508.48 10/05/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744026321
Principal investigator 1 SANOFI US SERVICES INC. $1,466.85 09/28/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744028681
Principal investigator 1 SANOFI US SERVICES INC. $302.55 09/28/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744028687
Principal investigator 1 SANOFI US SERVICES INC. $78.00 09/08/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 753386303
Principal investigator 1 SANOFI US SERVICES INC. $150.95 09/08/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 753386305
Principal investigator 1 SANOFI US SERVICES INC. $2,240.00 09/08/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 753386307
Principal investigator 1 SANOFI US SERVICES INC. $1,960.00 09/08/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 753386311
Principal investigator 1 SANOFI US SERVICES INC. $10,041.99 08/24/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744028667
Principal investigator 1 SANOFI US SERVICES INC. $11.05 08/04/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744028671
Principal investigator 1 SANOFI US SERVICES INC. $711.37 07/13/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744028591
Principal investigator 1 SANOFI US SERVICES INC. $15.29 06/29/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744028600
Principal investigator 1 SANOFI US SERVICES INC. $610.54 06/29/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744028605
Principal investigator 1 SANOFI US SERVICES INC. $9,173.93 06/29/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744028614
Principal investigator 1 SANOFI US SERVICES INC. $1,417.50 06/15/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744028585
Principal investigator 1 SANOFI US SERVICES INC. $1,800.00 06/02/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744028577
Principal investigator 1 SANOFI US SERVICES INC. $2,621.03 05/26/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744028571
Principal investigator 1 SANOFI US SERVICES INC. $27,334.15 05/18/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744028547
Principal investigator 1 SANOFI US SERVICES INC. $1,938.10 05/18/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744028555
Principal investigator 1 SANOFI US SERVICES INC. $35.35 05/18/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744028562
Principal investigator 1 SANOFI US SERVICES INC. $260.30 05/04/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744028953
Principal investigator 1 Hikma Pharmaceuticals USA $4,415.43 04/22/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
Fluticasone / Salmeterol Powder, 100mcg/50mcg Multicenter Clinical Endpoint Study No dispute reported 06/30/2026 717234331
Principal investigator 1 SANOFI US SERVICES INC. $30.47 03/03/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744026299
Principal investigator 1 SANOFI US SERVICES INC. $945.00 03/03/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744026305
Principal investigator 1 SANOFI US SERVICES INC. $173.00 03/03/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744026348
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,487.56 02/18/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma No dispute reported 06/30/2026 736750393
Principal investigator 1 SANOFI US SERVICES INC. $800.00 02/18/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744026291
Principal investigator 1 GlaxoSmithKline, LLC. $3,417.08 02/06/2020 Non-covered Recipient Entity
EMERALD COAST RESEARCH ASSOCIATES
A PHASE IV, 12 WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO C No dispute reported 06/30/2026 734905561
Principal investigator 1 SANOFI US SERVICES INC. $10,883.90 02/04/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744026285
Principal investigator 1 SANOFI US SERVICES INC. $11,249.56 01/27/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744026277
Principal investigator 1 AstraZeneca Pharmaceuticals LP $140,178.93 01/23/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) (COURSE) No dispute reported 06/30/2026 736736929
Principal investigator 1 SANOFI US SERVICES INC. $2,200.00 01/21/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744026269
Principal investigator 1 SANOFI US SERVICES INC. $330.00 01/07/2020 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 744028779